HPLC Analysis of Cisplatin Analogues in Biological Fluids

  • D. R. Newell
  • Z. H. Siddik
  • K. R. Harrap
Part of the Methodological Surveys in Biochemistry and Analysis book series (MSBA, volume 14)


The cisplatin analogues investigated relate to the search for a second generation Pt complex less toxic or more active than the parent compound. For cis-diammine(1,1-cyclobutane-dicarboxylato) platinum (CBDCA), normal-phase chromatography on silica with UV detection suffices down to levels of 10 μM in urine or plasma ultrafiltrates. Quantitation below 10 μM needs HPLC fraction collection followed by flameless atomic absorption spectrophotometry (FAAS; 0.5 μM detectable). These methods have been successfully applied to CBDCA in plasma and urine from patients and rats [1, 2]. For cis-dichloro- trans -dihydroxy bis (isopropylamine) platinum (CHIP), plasma ultrafiltrates were analyzed by HPLC on a μBondapak phenyl column with UV detection [3], or by water /methanol gradient elution from a μBondapak C-18 column followed by fraction collection and FAAS [4] (detection limits 1 μM and 0.04 μM respectively). Urines containing CHIP were analyzed by the latter method [3, 5]. These assays have been successfully applied to dog and human samples where besides CHIP, cis-dichloro-bis(isopropylamine)platinum has been found [3]. [Formulae are shown overleaf.-Ed.]


Fraction Collection Plasma Ultrafiltrate Phenyl Column Centrifugal Ultrafiltration Develop HPLC Method 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Harland, S.J., Newell, D.R., Siddik, Z.H., Chadwick, R., Calvert, A.H. & Harrap, 44. (1693) Cancer Res.44, 1693Google Scholar
  2. 2.
    Siddik, Z.H., Newell, D.R., Boxall, F.E., Jones, M., McGhee, K.G. & Harrap, K.R. (1984) in Platinum Coordination Complexes in Cancer Chemotherapy [Proc. IV Int. Platinum Symp., 1983](Hacker, M., Double, E. & Krakoff, I. eds.), Martinus Nijhoff, Boston, pp. 90 – 102.Google Scholar
  3. 3.
    Pendyala, L., Cowens, J.W., Madajewicz, S. & Creaven, P.J. (1984) as for 2., pp. 114–125.Google Scholar
  4. 4.
    Pendyala, L., Greco, W., Cowens, J.W., Madajewicz, S. & Creaven, P.J. (1983) Cancer Chemother. Pharmacol.11, 23 – 28.CrossRefGoogle Scholar
  5. 5.
    Pendyala, L., Cowens, J.W. & Creaven, P.J. (1982) Cancer Treatm. Rep. 66, 509 – 516.Google Scholar
  6. 6.
    van der Vijgh, W.J.F., van der Lee, H.B.J., Postma, G.J. & Pinedo, H.M. (1983) Chromatographia 8, 333 – 336.CrossRefGoogle Scholar
  7. 7.
    Kelsen, D.P., Scher, H., Alcock, N., Leyland-Jones, B.,Donner, A., Williams, L., Greene, G., Burchenal, J.H., Tan, C., Philips, F.S. & Young, C.W. (1982) Cancer Res. 42, 4831 – 4835Google Scholar
  8. 8.
    Harrap, K.R. (1983) in Cancer Chemotherapy I(Muggia, F.M., ed.), Nijhoff, The Hague, pp. 171 – 217.CrossRefGoogle Scholar
  9. 9.
    Himmelstein, K.J., Patton, T.F., Belt, R.J., Taylor, S., Repta, A.J. & Sternson, L.A. (1981) Clin. Pharmacol. Ther. 29, 658 – 664.CrossRefGoogle Scholar
  10. 10.
    Riley, C.M., Sternson, L.A., Repta, A.J. & Siegler, R.W. (1982) J. Chromatog. 229, 373 – 386.CrossRefGoogle Scholar
  11. 11.
    Krull, I.S., Ding, X-D., Braverman, S., Selavka, C., Hochberg, F. & Sternson, L.A. (1983) J.Chromatog. Sci. 21, 166 – 173Google Scholar
  12. 12.
    Kelsen, D., Scher, H. & Burchenal, J. (1984) as for 2., pp. 310–320.Google Scholar

Copyright information

© Plenum Press, New York 1984

Authors and Affiliations

  • D. R. Newell
    • 1
  • Z. H. Siddik
    • 1
  • K. R. Harrap
    • 1
  1. 1.Department of Biochemical PharmacologyInstitute of Cancer ResearchSuttonSurrey, UK

Personalised recommendations